Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-11-21
2006-11-21
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S375000, C435S377000, C536S024100, C536S024500
Reexamination Certificate
active
07138380
ABSTRACT:
Disclosed are transgenic animals and transfected cell lines expressing a protein associated with Alzheimer's Disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. Also disclosed is the use of such transgenic animals and transfected cell lines to screen potential drug candidates for treating or preventing Alzheimer's disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. The invention also relates to new antisense oligonucleotides, ribozymes, triplex forming DNA and external guide sequences that can be used to treat or prevent Alzheimer's disease, neuroectodermnal tumors, malignant astrocytomas, and glioblastomas.
REFERENCES:
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5168053 (1992-12-01), Altman et al.
patent: 5830670 (1998-11-01), de la Monte et al.
patent: 5948634 (1999-09-01), de la Monte et al.
patent: 5948888 (1999-09-01), de la Monte et al.
patent: 6071705 (2000-06-01), Wands et al.
patent: 6245523 (2001-06-01), Altieri
patent: 0 263 740 (1988-04-01), None
patent: WO 89/03849 (1989-05-01), None
patent: WO 90/06993 (1990-06-01), None
patent: WO 92/07065 (1992-04-01), None
patent: WO 94/23756 (1994-10-01), None
patent: WO 96/15272 (1996-05-01), None
patent: WO 96/40895 (1996-12-01), None
Branch A., TIBS vol. 23:45-50, Feb. 1998.
Jen et al., Stem Cells vol. 18: 307-319, 2000.
Agrawal S., TIBTECH vol. 14:376-387, Oct. 1996.
Linder, C.C., “The Influence of Genetic Background on Spontaneous and Genetically Engineered Mouse Models of Complex Diseases,”Lab Animal 30:34-39, Nature America (May 2001).
Frangiskakis, J.M., et al., “LIM-kinaselHemizygosity Implicated in Impaired Visuospatial Constructive Cognition,”Cell 86:59-69, Cell Press (Jul. 1996).
Rülicke, T., and Hübscher, U., “Germ line transformation of mammals by pronuclear microinjection,”Exp. Physiol. 85:589-601, The Physiological Society (Nov. 2000).
Strojek, R.M., and Wagner, T.E., “The Use of Transgenic Animal Techniques for Livestock Improvement,”Genet. Eng. 10:221-246, Plenum Press (1988).
Houdebine, L.-M., “Production of pharmaceutical proteins from transgenic animals,”J. Biotechnol. 34:269-287, Elsevier Science B.V. (1994).
Mullins, L.J., and Mullins, J.J., “Transgenesis in the Rat and Larger Mammals,”J. Clin. Invest. 97:1557-1560, The American Society for Clinical Investigation, Inc. (Apr. 1996).
Bishop, J.O., “Chromosomal insertion of foreign DNA,”Reprod. Nutr. Dev. 36:607-618, Elsevier/INRA (Nov.-Dec. 1996).
Polejaeva, I.A., and Campbell, K.H.S., “New Advances in Somatic Cell Nuclear Transfer: Application in Transgenesis,”Theriogenology 53:117-126, Elsevier Science Inc. (Jan. 2000).
Wall, R.J., “Transgenic Livestock: Progress and Prospects for the Future,”Theriogenology 45:57-68, Elsevier Science Inc. (Jan. 1996).
Sigmund, C.D. “Viewpoint: Are Studies in Genetically Altered Mice Out of Control?”Arterioscler. Thromb. Vasc. Biol. 20:1425-1429, Lippincott Williams & Wilkins (Jun. 2000).
Chiu, T.-L., and Goldstein, R.A., “Optimizing energy potentials for success in protein tertiary structure prediction,”Fold. Des. 3:223-228, Current Biology Ltd. (May 1998).
Ngo, J.T., et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” inThe Protein Folding Problem and Tertiary Structure Prediction, Merz, K. Jr., and Le Grand, S., eds., Birkhauser, Boston, MA, pp. 491-495 (1994).
Yamada, K., and Nabeshima, T., “Animal models of Alzheimer's disease and evaluation of anti-dementia drugs,”Pharmacol. Ther. 88:93-113, Elsevier Science Inc. (Nov. 2000).
Anderson, W.F., “Human gene therapy,”Nature 392:25-30, Macmillan Journals Ltd. (Apr. 1998).
Bloch, D.B., et al., “Identification and Characterization of a Leukocyte-specific Component of the Nuclear Body,”J. Biol. Chem. 271:29198-29204, The American Society for Biochemistry and Molecular Biology, Inc. (Nov. 1996).
Brinster, R.L., et al., “Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs,”Proc. Natl. Acad. Sci. USA 82:4438-4442, National Academy of Sciences (1985).
Chiu, T.-L. and Goldstein, R.A., “Optimizing energy potentials for success in protein tertiary structure prediction,”Folding and Design 3:223-228, Current Biology Ltd. (May 1998).
de la Monte, S.M., et al., “Enhanced Expression of an Exocrine Pancreatic Protein in Alzheimer's Disease and the Developing Human Brain,”J. Clin. Invest. 86:1004-1013, The American Society for Clinical Investigation, Inc. (1990).
de la Monte, S.M., et al., “Regional and Maturation-associated Expression of Endothelin 2 in Rat Gastrointestinal Tract,”J. Histochem. Cytochem. 43:203-209, The Histochemical Society, Inc. (1995).
de la Monte, S.M., et al., “Aberrant GAP-43 Gene Expression in Alzheimer's Disease,”Am. J. Pathol. 147:934-946, American Society for Investigative Pathology (1995).
de la Monte, S.M., and Bloch, K.D., “Aberrant Expression of the Constitutive Endothelial Nitric Oxide Synthase Gene in Alzheimer Disease,”Mol. Chem. Neuropathol. 30:139-159, Humana Press, Inc. (Jan./Feb. 1997).
Games, D., et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein,”Nature 373:523-527, Macmillan Journals Ltd. (1995).
Gossler, A., et al., “Transgenesis by means of blastocyst-derived embryonic stem cell lines,”Proc. Natl. Acad. Sci. USA 83:9065-9069, National Academy of Science (1986).
Gross, J., et al., “Isolation Characterization, and Distribution of an Unusual Pancreatic Human Secretory Protein,”J. Clin. Invest. 76:2115-2126, The American Society for Clinical Investigation, Inc. (1985).
The Huntington's Disease Collaborative Research Group, “A Novel Gene Containing a Trinucleotide Repeat That Is Expanded and Unstable on Huntington's Disease Chromosomes,”Cell 72:971-983, Cell Press (1993).
Kosaka, K., “Dementia and Neuropathology in Lewy Body Disease,”Adv. Neurol. 60:456-463, Raven Press. Ltd. (1993).
Lannfelt, L., et al., “Alzheimer's disease: molecular genetics and transgenic animal models,”Behav. Brain Res. 57:207-213, Elsevier Science B.V. (1993).
Marx, J., “Major Setback for Alzheimer's Models,”Science 255:1200-1202, American Association for the Advancement of Science (1992).
Ozturk, M., et al., “Elevated levels of an exocrine pancreatic secretory protein in Alzheimer disease brain,”Proc. Natl. Acad. Sci. USA 86:419-423, National Academy of Sciences (1989).
Pursel, V.G., et al., “Genetic Engineering of Livestock,”Science 244:1281-1288, American Association for the Advancement of Science (1989).
Quon, D., et al., “Formation of β-amyloid protein deposits in brains of transgenic mice,”Nature 352:239-241, Macmillan Journals Ltd. (1991).
Salter, D.W., et al., “Transgenic Chickens: Insertion of Retroviral Genes into the Chicken Germ Line,”Virology 157:236-240, Academic Press, Inc. (1987).
Verma, I.M. and Somia, N., “Gene Therapy- promises, problems and prospects,”Nature 389:239-242, Macmillan Journals Ltd. (Sep. 1997).
Dialog File 351, Accession No. 88-100135/198815, Derwent WPI English language abstract for EP 0 263 740 (Document AL1).
International Search Report for International Application No. PCT/US98/03685, mailed Jul. 9, 1998.
Pending Non-Provisional U.S. Appl. No. 09/380,203, de la Monte et al., filed Apr. 25, 2000 and U.S. Appl. No. 09/964,678, 09/964,666 and 09/964,667, de la Monte et al., filed Sep. 28, 2001.
Claims Currently Pending from U.S. Appl. No. 09/380,203, de la Monte et al., filed Apr. 25, 2000.
Claims Currently Pending from U.S. Appl. No. 09/964,678, de la Monte et al., filed Sep. 28, 2001.
Claims Currently Pending from U.S. Appl. No. 09/964,666, de la Monte et al., filed Sep
De La Monte Suzanne
Wands Jack R
McGarry Sean
Sterne Kessler Goldstein & Fox P.L.L.C.
The General Hospital Corporation
LandOfFree
Transgenic animals and cell lines for screening drugs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic animals and cell lines for screening drugs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic animals and cell lines for screening drugs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3652303